About Pingene

　　Zhejiang grade Gene Technology Co., Ltd., established in June 2018, is located in Zhoushan free trade (experimental) zone, Zhejiang Province, with a registered capital of 32 million yuan. It is a professional company integrating R & D, production and sales of cancer detection kits. It is a high-tech enterprise introduced by Zhoushan Municipal Government. In 2020, it will be listed as "Zhejiang science and technology SMEs".

　　The company has successfully developed a series of in vitro detection products of "cancer liquid gene detection" with completely independent intellectual property rights, and applied the unique technology of adding molecular barcode to the determination of circulating tumor DNA (ctDNA), so as to dynamically track the real-time changes of cancer occurrence and progress. Compared with similar products at home and abroad, the company has the advantages of "more accurate, more sensitive and more reliable" The main indexes have exceeded or reached the international advanced level. At present, we are preparing to apply for the national class III medical device registration certificate.

　　In 2018, Zhoushan grade medical laboratory Co., Ltd., a third-party medical testing institution, was registered with 5 million yuan. The company uses the core technology developed by the parent company and adopts the "LDT" mode to carry out cancer gene detection services.

　　The company covers an area of 2600 square meters, with "molecular laboratory" and complete and professional DNA testing laboratory, "GMP production workshop" covering an area of 1800 square meters, and "clean testing laboratory" covering an area of 500 square meters. All of them have obtained the third party GMP environmental certification and qualification certification.

　　The company has miseq DX sequencer, Bio-Rad, veriti, qsep and other equipment, as well as self-developed sequencing software and server.

　　The technology leader of the company is Dr. Lin Yunfu, who is under the guidance of Professor Tan Jiazhen (academician of Chinese Academy of Sciences, foreign academician of American Academy of Sciences and Italian Academy of Sciences). Professor and researcher of Anderson Cancer Center. For more than 30 years, he has been engaged in the academic research of molecular genetics and molecular oncology. He has published 35 research papers and 6 reviews in first-class journals such as "nature molecular biology" and "Proceedings of the American Academy of Sciences", and participated in the compilation of a monograph. As the editorial board member of many academic journals, he has been invited to speak at international academic conferences for many times. Google's H academic index is 21. In 2017, he returned to China and established the company.

　　The company, together with experts and professors from Fudan University, Chongqing Medical University, Peking Union Medical College Hospital, Zhejiang University and other famous universities and hospitals in China, has established a technical team from academic to clinical.

The value of product existence

　　"Precision treatment" is the main development trend of medicine in the future. The premise of "precision treatment" is "precision diagnosis". Our products belong to the subdivision of "precision diagnosis" of cancer.

　　In 2015, 4.292 million new cancer patients and 2.814 million deaths were reported; Over the past 10 years, the number of cancers has increased by an average of 3.9% every year. According to this growth rate, it is estimated that the number of new cancer patients will reach 5 million in 2019.

In 2015, liquid biopsy was rated as the top ten technological breakthroughs of the year by MIT; In June 2017, the world economic forum and the expert committee of Scientific American jointly selected the top ten emerging technologies in the world in 2017, among which the noninvasive diagnosis technology of tumor was selected successfully and won the first place.

　　Piper Jaffray predicted that the optimistic, neutral and pessimistic market space of tumor liquid biopsy is about 150 billion yuan, 112.5 billion yuan and 75 billion yuan respectively. According to the above analysis, by 2025, our predicted cancer liquid biopsy market will be about 90 billion yuan, which is between Piper Jaffray's pessimistic and neutral prediction. According to incomplete statistics, China's tumor liquid biopsy market in 2019 is about 13 billion yuan.

1. Healthy people: mainly used for early warning of cancer;

2. Patient population: mainly used in cancer postoperative evaluation, concomitant diagnosis, recurrence monitoring, medication guidance

Based on two patents (Chinese invention patents: 201810193450.5 and 201810193448.8) independently developed by our company with full intellectual property rights, we use them for gene detection including cancer gene detection.

This patent technology is different from the current technical route and detection method. We are quantitative determination of ctDNA or ccfdna in body fluid. In other words, we are detecting the absolute value of ctDNA or ccfdna in body fluid, rather than the ratio of ctDNA and ccfdna. This is the first detection method at home and abroad, with milestone significance!

　　The detection limit of the company's products is at least two times lower than that of the current market products. Therefore, it is of great clinical significance to detect cancer and cancer recurrence earlier.